5

FOX News Channel Finishes First Quarter of 2023 as Top Network in All of Cable With Viewers Across Primetime and Total Day

Retrieved on: 
Tuesday, March 28, 2023
TV and Radio, Communications, Entertainment, Publishing, FOX, America Reports, Cavuto Live, Media Buzz, One Nation, Story, The Late Show, The Next Revolution, VS, Fox, Fox & Friends, Fox News, The Tonight Show, Saturday, History, CNN, MSNBC, FNC, Angle, Liberty, Greg Gutfeld, NEWS, The Ingraham Angle, News, Nielsen Media Research, Ingraham, Television, Friends, 5, The Sundays

FOX News Channel (FNC) finished the first quarter of 2023 as cable’s most-watched network in primetime and total day viewers, according to Nielsen Media Research.

Key Points: 
  • FOX News Channel (FNC) finished the first quarter of 2023 as cable’s most-watched network in primetime and total day viewers, according to Nielsen Media Research.
  • Additionally, FNC beat CNN and MSNBC combined with total day and primetime viewers and the A25-54 demo for the seventh consecutive quarter.
  • With primetime viewers in cable news, this marked the 85th straight quarter that FNC has been number one.
  • FNC was the number one cable network during total day among Asian viewers and the top cable news network with Hispanic viewers across both primetime and total day.

Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout November

Retrieved on: 
Tuesday, November 1, 2022
Technology, Medical Devices, Diabetes, Biotechnology, Other Education, General Health, Pharmaceutical, Health, Consumer Electronics, Education, Awareness, Life, 5, Nasdaq, JDRF, National Diabetes Education Program, Insulin pump, POD, Injection, Sasuke (TV series), Technology, Adoption, American Ninja Warrior, NASDAQ, Company, World Diabetes Day, Patient, Multimedia, Corporation, Type 1 diabetes, Diabetes, Pharmaceutical industry

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced a variety of educational campaigns and activities in recognition of National Diabetes Awareness Month and World Diabetes Day.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced a variety of educational campaigns and activities in recognition of National Diabetes Awareness Month and World Diabetes Day.
  • Our team is relentless in our mission to improve the lives of people with diabetes around the world, said President and CEO Jim Hollingshead.
  • November is the perfect time to acknowledge the diabetes community and create awareness for the daily challenges that our customers face.
  • The Insulet team will appear at the Nasdaq Stock Market for the eighth consecutive year by virtually ringing the closing bell on Monday, November 14, World Diabetes Day.

Profiles of Five Major Corporations With In-House Technical Textile Filter Media Manufacturing Operations: 3M, Cummins, Danaher Corporation, Filtration Group, & Parker Hannifin Corporation - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Technology, Automotive, Biotechnology, Machinery, Other Manufacturing, Machine Tools, Metalworking & Metallurgy, HVAC, Textiles, Health, Automotive Manufacturing, Other Technology, Manufacturing, Software, Hardware, EV, Electric Vehicles, Pharmaceutical, Data Management, Parker Hannifin, Industry, Textile, Growth, Investment, Intelligence, Danaher Corporation, 5, Fine chemical

The "Profiles of Five Major Corporations With In-House Technical Textile Filter Media Manufacturing Operations" report from Textiles Intelligence Ltd. has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Profiles of Five Major Corporations With In-House Technical Textile Filter Media Manufacturing Operations" report from Textiles Intelligence Ltd. has been added to ResearchAndMarkets.com's offering.
  • This report provides information about the activities, investments, marketing strategies and product strategies of five major companies with filter media operations, namely: 3M; Cummins; Danaher Corporation; Filtration Group; and Parker Hannifin Corporation.
  • The report also provides data on the size of the filtration market and sales achieved by these five companies.
  • The filtration industry is highly diversified and serves a global market which is large and fast growing.

AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS

Retrieved on: 
Wednesday, October 12, 2022
Education, Therapy, Mayo Clinic, Head, Support, NASDAQ, Lists of disasters, Patent, Crohn's & Colitis Foundation, Board of directors, Public expenditure, Failure, Solution, Adoption, News, Pandemic, Barron's, Access, Confidentiality, Marketing, Clinical trial, FDA, AMGN, Movement, Government, Growth, Biology, Research, Security (finance), Annual report, Technology, Form 10-K, Biosimilar, U.S. Securities and Exchange Commission, Genetics, BeiGene, Apremilast, Physician, Disease, Clinical professor, Dow Jones Industrial Average, Patient, Biotechnology, Form 8-K, Globalization, Report, EPS, Acquisition, IBD, Safety, 5, Forward-looking statement, COVID-19, 100 Best Workplaces in Europe, Generic drug, Fine chemical, Pharmaceutical industry, Amgen

THOUSAND OAKS, Calif., Oct. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S. marketplace with biosimilars. This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars. To access the full Report, visit https://www.amgenbiosimilars.com/commitment/trends-report.

Key Points: 
  • This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars.
  • "Our 2022 Biosimilar Trends Report found that the marketplace with biosimilars is well established, and the U.S. is poised to see continued growth in biosimilar approvals.
  • New data from the Report confirm that biosimilar uptake in the U.S. continues to increase over time, resulting in significant market share in most therapeutic areas where biosimilars have been introduced.
  • We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA

Retrieved on: 
Thursday, October 6, 2022
Fitwell, News, Adoption, U.S. Securities and Exchange Commission, Bay, Movement, Disease, Therapy, Government, Human Rights Campaign, Pandemic, Inflammation, Growth, Fortune, HRC, Forbes, LEED, Dow Jones Industrial Average, Diversity, NASDAQ, Patient, Barron's, Biotechnology, Form 8-K, Biology, Corporate Equality Index, Research, Annual report, Confidentiality, Security (finance), Cancer, Technology, San Francisco Bay Area, Form 10-K, EPS, Acquisition, Marketing, Lists of disasters, Patent, Safety, Workplace, 5, American, Genetics, Clinical trial, Board of directors, Public expenditure, American City Business Journals, Oyster Point, Forward-looking statement, BeiGene, Failure, Simultaneous recruiting of new graduates, COVID-19, AMGN, Apremilast, Solution, 100 Best Workplaces in Europe, Pharmaceutical industry, Amgen

THOUSAND OAKS, Calif., Oct. 6, 2022 /PRNewswire/ -- (Oct. 6, 2022) – Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Francisco's Oyster Point, continuing the company's nearly two-decade presence in the region. The new site will constitute the company's second largest research and development facility, which focuses on discovering therapeutics for patients living with cancer, inflammatory disease and cardiometabolic disorders.

Key Points: 
  • The new site will constitute the company's second largest research and development facility, which focuses on discovering therapeutics for patients living with cancer, inflammatory disease and cardiometabolic disorders.
  • "For nearly two decades Amgen has been present in the San Francisco Bay Area, a region known for cutting-edge science and biotechnology innovation," said Robert A. Bradway, chairman and chief executive officer of Amgen.
  • "Our new site is home to a perfect combination of technology and biotech innovation, making Amgen an attractive place for local scientific professionals looking to build an inspirational, rewarding career," says Saptarsi Haldar, vice president of cardiometabolic research and site head for Amgen San Francisco.
  • This year, the San Francisco Business Times recognized Amgen San Francisco as one of the "Best Places to Work" in the Bay Area.Earlier in 2022, Forbes named Amgen for the fourth straight year as one of "America's Best Employers for Diversity" as well as one of "America's Best Employers for New Graduates.

DEATHVERSE: LET IT DIE Launches on PlayStation Today

Retrieved on: 
Wednesday, September 28, 2022
Retail, Online, Consumer Electronics, Mobile Entertainment, Technology, General Entertainment, Women, Online Retail, Teens, Men, Electronic Games, Specialty, Entertainment, Consumer, Internet, Online, Master, Health, 5, PlayStation Store, Metro, Circular saw, HDR, PlayStation, XSEED, Exhibition, Mushroom, Collection, Process Church of the Final Judgment, Survivor, Voltage, GungHo Online Entertainment, Unit, Wilson, Game Arts, Steam, Survival, Machete, PlayStation 4, Weapon, Rotation, LET, Friends, CA, DIE, Judgement, GOE, Multimedia, Skin, Xseed Games, Video game console, Hunting, Video game, Season

GungHo Online Entertainment and SUPERTRICK GAMES today launched DEATHVERSE: LET IT DIE on PlayStation 5 and PlayStation 4.

Key Points: 
  • GungHo Online Entertainment and SUPERTRICK GAMES today launched DEATHVERSE: LET IT DIE on PlayStation 5 and PlayStation 4.
  • This free-to-play, multiplayer action game is a spiritual spinoff to LET IT DIE and can be downloaded from the PlayStation Store .
  • DEATHVERSE: LET IT DIE will launch on PC next Wednesday, October 5, and can be wishlisted on Steam here .
  • In DEATHVERSE: LET IT DIE, players compete in a 16-player survival battle arena as contestants of the world-renowned television program DEATH JAMBOREE.

Fierce Whiskers Launches World's First Carbon-Negative Bourbon

Retrieved on: 
Friday, September 23, 2022
Carbon, Glass, Madison Brass Works, Organization, Grain, Barrel, Certification, Silent Scope 3, Carbon footprint, Map, 5, Water, Oil, Renewable energy, Fierce

AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter, a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas. Five O'Clock Shadow, a single-barrel bourbon release dropping exclusively at the company's first-anniversary event on September 24, 2022, also represents the first bourbon release for this grain-to-grass distillery.

Key Points: 
  • CarbonBetter today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter , a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • "At Fierce Whiskers, we are singularly focused on making the best possible whiskey in Austin, Texas.
  • The work to measure, reduce, and report on Fierce Whiskers' impacts set the stage to release a carbon-negative bourbon by leveraging carbon intensity calculations.

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Pharmaceutical, General Health, Health, Diabetes, Medical Devices, Consumer Electronics, Technology, Risk, POD, Safety, Injection, 5, Insulin pump, Corporation, Company, European Association for the Study of Diabetes, Glucose, Diabetes, U.S. Securities and Exchange Commission, Paracetamol, Insulin, CEO, Technology, European Medical Writers Association, Annual report, CGM, T1D, NASDAQ, G6, Ageing, Security (finance), Association, EASD, Medical device, Pharmaceutical industry, Copper, Dexcom

Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels 1.

Key Points: 
  • Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels 1.
  • The system then increases, decreases, or pauses insulin delivery based on the users desired and customized glucose target.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • Insulets latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks3.

Embark on a Brand-New Journey in OCTOPATH TRAVELER II, Launching February 24, 2023

Retrieved on: 
Tuesday, September 13, 2022
Electronic Games, Technology, Entertainment, Electronic Commerce, Audio, Video, Software, Retail, Consumer Electronics, Online Retail, Clergy, Element, 5, Nintendo Switch, PlayStation, Scholar, PS4, Warrior, Merchant, Nintendo Direct, Character, Non-player character, PlayStation 4, ART, SQUARE, Nintendo, STEAM, PS5, RPG, 2D, Video game console, Entertainment

Watch the OCTOPATH TRAVELER II announcement trailer here: https://youtu.be/XMpWElRyoxg .

Key Points: 
  • Watch the OCTOPATH TRAVELER II announcement trailer here: https://youtu.be/XMpWElRyoxg .
  • In OCTOPATH TRAVELER II, players will embark on an exciting journey through the brand-new world of Solistia.
  • Path Actions Players can interact with NPCs throughout the world in various ways by using actions unique to each character.
  • OCTOPATH TRAVELER II will be available to pre-order within the next 24 hours** in a Standard Digital Edition for PS5, PS4 and PC via STEAM.

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Retrieved on: 
Monday, September 12, 2022
Software, Biotechnology, General Health, Health, Data Management, Health Technology, Technology, Genetics, Therapy, Gene editing, Chemical engineering, CRISPR, CIO, Therapeutic Targets Database, Senior, Acquisition, Growth, Industry, Berkeley, CEO, MBA, Amgen, Cancer, Nanotechnology, Notre Dame Institute for Global Investing, 5, Biotechnology, University of Washington Department of Bioengineering, Hemoglobinopathy, Multimedia, University, Management, Medical device, Pharmaceutical industry, Spotlight

Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.

Key Points: 
  • Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220912005015/en/
    "We are delighted to welcome Arvind to Spotlights leadership team.
  • "Arvind has deep experience in biologics and will play a key role in helping Spotlight bring a new class of CRISPR ribonucleoprotein therapeutics to patients.
  • Established in 2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies.